Hayallah Alaa M, Sandoval-Ramírez Jesús, Reith Ulrike, Schobert Ulrike, Preiss Birgit, Schumacher Britta, Daly John W, Müller Christa E
University of Bonn, Pharmaceutical Institute Poppelsdorf, Bonn, Germany.
J Med Chem. 2002 Mar 28;45(7):1500-10. doi: 10.1021/jm011049y.
3-Unsubstituted xanthine derivatives bearing a cyclopentyl or a phenyl residue in the 8-position were synthesized and developed as A2B adenosine receptor antagonists. Compounds bearing polar substituents were prepared to obtain water-soluble derivatives. 1-Alkyl-8-phenylxanthine derivatives were found to exhibit high affinity for A2B adenosine receptors (ARs). 1,8-disubstituted xanthine derivatives were equipotent to or more potent than 1,3,8-trisubstituted xanthines at A2B ARs, but generally less potent at A1 and A2A, and much less potent at A3 ARs. Thus, the new compounds exhibited increased A2B selectivity versus all other AR subtypes. 9-Deazaxanthines (pyrrolo[2,3-d]pyrimidindiones) appeared to be less potent at A2B ARs than the corresponding xanthine derivatives. 1-Propyl-8-p-sulfophenylxanthine (17) was the most selective compound of the present series, exhibiting a K(i) value of 53 nM at human A2B ARs and showing greater than 180-fold selectivity versus human A1 ARs. Compound 17 was also highly selective versus rat A1 ARs (41-fold) and versus the other human AR subtypes (A2A > 400-fold and A3 > 180-fold). The compound is highly water-soluble due to its sulfonate function. 1-Butyl-8-p-carboxyphenylxanthine (10), another polar analogue bearing a carboxylate function, exhibited a K(i) value of 24 nM for A2B ARs, 49-fold selectivity versus human and 20-fold selectivity versus rat A1 ARs, and greater than 150-fold selectivity versus human A2A and A3 ARs. 8-[4-(2-Hydroxyethylamino)-2-oxoethoxy)phenyl]-1-propylxanthine (29) and 1-butyl-8-[4-(4-benzyl)piperazino-2-oxoethoxy)phenyl]xanthine (35) were among the most potent A2B antagonists showing K(i) values at A2B ARs of 1 nM, 57-fold (29) and 94-fold (35) selectivity versus human A1, ca. 30-fold selectivity versus rat A1, and greater than 400-fold selectivity versus human A2A and A3 ARs. The new potent, selective, water-soluble A2B antagonists may be useful research tools for investigating A2B receptor function.
合成了在8位带有环戊基或苯基残基的3-未取代黄嘌呤衍生物,并将其开发为A2B腺苷受体拮抗剂。制备了带有极性取代基的化合物以获得水溶性衍生物。发现1-烷基-8-苯基黄嘌呤衍生物对A2B腺苷受体(ARs)表现出高亲和力。在A2B ARs上,1,8-二取代黄嘌呤衍生物与1,3,8-三取代黄嘌呤等效或更具活性,但在A1和A2A受体上通常活性较低,在A3 ARs上活性则低得多。因此,新化合物对所有其他AR亚型的A2B选择性增加。9-脱氮黄嘌呤(吡咯并[2,3-d]嘧啶二酮)在A2B ARs上的活性似乎低于相应的黄嘌呤衍生物。1-丙基-8-对磺基苯基黄嘌呤(17)是本系列中最具选择性的化合物,在人A2B ARs上的K(i)值为53 nM,对人A1 ARs的选择性大于180倍。化合物17对大鼠A1 ARs(41倍)以及其他人AR亚型(A2A > 400倍和A3 > 180倍)也具有高度选择性。由于其磺酸盐功能,该化合物具有高度水溶性。1-丁基-8-对羧基苯基黄嘌呤(10)是另一种带有羧酸盐功能的极性类似物,对A2B ARs的K(i)值为24 nM,对人A1 ARs的选择性为49倍,对大鼠A1 ARs的选择性为20倍,对人A2A和A3 ARs的选择性大于150倍。8-[4-(2-羟乙氨基)-2-氧代乙氧基]苯基]-1-丙基黄嘌呤(29)和1-丁基-8-[4-(4-苄基)哌嗪-2-氧代乙氧基]苯基黄嘌呤(35)是最有效的A2B拮抗剂之一,在A2B ARs上的K(i)值为1 nM,对人A1的选择性为57倍(29)和94倍(35),对大鼠A1的选择性约为30倍,对人A2A和A3 ARs的选择性大于400倍。新型强效、选择性、水溶性A2B拮抗剂可能是研究A2B受体功能的有用研究工具。